RELATIONSHIP BETWEEN TFPI GENE POLYMORPHISMS, POST-COVID-19 CONDITION AND D-DIMER LEVELS IN PATIENTS WITH HISTORY OF COVID-19

Résumé fourni par la source

Coronavirus Disease 2019 (COVID-19) is a highly contagious respiratory illness associated with systemic inflammation. Post-COVID-19 condition (PCC) refers to persistence or development of new clinical findings 3-months after COVID-19 infection, lasting for at least 2-months, without another explanation. Given that COVID-19 is associated with hemostatic disturbances, and a thrombophilic state, we have investigated the relationship between Tissue Factor Pathway Inhibitor (TFPI) Polymorphisms (TFPI -33T>C [rs8176592] and -399C>T [rs10153820]), D-dimer levels and the occurrence of PCC. A total of 144 patients with confirmed molecular diagnosis for COVID-19 between 2020‒2022 attended at the Hospital Universitário Antônio Pedro were included in this cross-sectional study. This study was approved by the Research Ethics Committee of the Universidade Federal Fluminense (CAAE: 59213722.5.0000.5243). Patients were recruited between July 2022 and July 2023. PCC diagnosis was performed according to the World Health Organization guidelines (2022). D-dimer levels were assessed by automated methods. Whole blood DNA was isolated for genetic polymorphisms analyses. Genotypes for TFPI -33T>C and -399C>T were obtained by allelic discrimination using quantitative polymerase chain reaction with TaqMan® assays. The median (interquartile range) age of the patients was 57 (45‒65) years. One hundred and four individuals (72.2%) were female. No differences were observed in D-dimer levels between patients according to PCC diagnosis, hospitalization during acute phase, or among genotypes for TFPI -399C>T and -33T>C. No associations were found between genotypes for TFPI -399C>T and PCC diagnosis, hospitalization during acute phase, or with elevated D-dimer levels (> 500 ng/mL) (p > 0.05). However, carriers of TFPI -33CT presented a higher risk for hospitalization (OR = 3.74; 95% CI 1.41‒9.97; p = 0.008), while the TFPI -33CC genotype had a protective effect (OR = 0.25: 95% CI 0.07‒ 0.91; p = 0.035). No association was found between TFPI -33T>C and PCC or elevated D-dimer levels (p > 0.05). It is important to explore whether genes related to hemostasis such as TFPI, which encodes an anticoagulant protein, may contribute to clinical outcomes in COVID-19 and subsequently for PCC development. TFPI -399C>T and -33T>C polymorphisms are associated with increased gene expression and higher TFPI levels, and lower risk of thromboembolic events. We did not observe associations between these polymorphisms and PCC. However, we demonstrated that homozygous carriers of TFPI -33T>C may have lower risk for hospitalization during the acute phase of COVID-19. Our preliminary data has shown that TFPI -399C>T and -33T>C are not associated with the occurrence of PCC. However, homozygosity for TFPI -33T>C may predict a lower risk for hospital admission during COVID-19.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.